Thirlwell C, Howarth K M, Segditsas S, Guerra G, Thomas H J W, Phillips R K S, Talbot I C, Gorman M, Novelli M R, Sieber O M, Tomlinson I P M
Molecular and Population Genetics Laboratory, London Research Institute, Cancer Research UK, 44, Lincoln's Inn Fields, London WC2A 3PX, UK.
Br J Cancer. 2007 Jun 4;96(11):1729-34. doi: 10.1038/sj.bjc.6603789. Epub 2007 May 15.
Patients with multiple (5-100) colorectal adenomas (MCRAs) often have no germline mutation in known predisposition genes, but probably have a genetic origin. We collected a set of 25 MCRA patients with no detectable germline mutation in APC, MYH/MUTYH or the mismatch repair genes. Extracolonic tumours were absent in these cases. No vertical transmission of the MCRA phenotype was found. Based on the precedent of MYH-associated polyposis (MAP), we searched for a mutational signature in 241 adenomatous polyps from our MCRA cases. Somatic mutation frequencies and spectra at APC, K-ras and BRAF were, however, similar to those in sporadic colorectal adenomas. Our data suggest that the genetic pathway of tumorigenesis in the MCRA patients' tumours is very similar to the classical pathway in sporadic adenomas. In sharp contrast to MAP tumours, we did not find evidence of a specific mutational signature in any individual patient or in the overall set of MCRA cases. These results suggest that hypermutation of APC does not cause our patients' disease and strongly suggests that MAP is not a paradigm for the remaining MCRA patients. Our MCRA patients' colons showed no evidence of microadenomas, unlike in MAP and familial adenomatous polyposis (FAP). However, nuclear beta-catenin expression was significantly greater in MCRA patients' tumours than in sporadic adenomas. We suggest that, at least in some cases, the MCRA phenotype results from germline variation that acts subsequent to tumour initiation, perhaps by causing more rapid or more likely progression from microadenoma to macroadenoma.
患有多发性(5 - 100个)结直肠腺瘤(MCRAs)的患者在已知的易感基因中通常没有种系突变,但可能有遗传起源。我们收集了一组25例MCRAs患者,这些患者在APC、MYH/MUTYH或错配修复基因中未检测到种系突变。这些病例中没有结肠外肿瘤。未发现MCRAs表型的垂直传递。基于MYH相关息肉病(MAP)的先例,我们在我们的MCRAs病例的241个腺瘤性息肉中寻找突变特征。然而,APC、K-ras和BRAF的体细胞突变频率和谱与散发性结直肠腺瘤中的相似。我们的数据表明,MCRAs患者肿瘤发生的遗传途径与散发性腺瘤中的经典途径非常相似。与MAP肿瘤形成鲜明对比的是,我们在任何个体患者或整个MCRAs病例组中都没有发现特定突变特征的证据。这些结果表明,APC的超突变不会导致我们患者的疾病,并强烈表明MAP不是其余MCRAs患者的范例。与MAP和家族性腺瘤性息肉病(FAP)不同,我们的MCRAs患者的结肠没有微腺瘤的证据。然而,MCRAs患者肿瘤中的核β-连环蛋白表达明显高于散发性腺瘤。我们认为,至少在某些情况下,MCRAs表型是由肿瘤起始后起作用的种系变异导致的,可能是通过使从微腺瘤到腺瘤的进展更快或更有可能发生。